| Polycystic Kidney Disease |
| Classification and external resources |
| ICD-10 |
Q61 |
| ICD-9 |
753.1 |
| OMIM |
263200 |
| DiseasesDB |
10280 |
| MedlinePlus |
000502 |
| eMedicine |
radio/69 |
| MeSH |
D017044 |
| GeneReviews |
- Polycystic Kidney Disease, Autosomal Recessive
|
ARPKD is inherited in an autosomal recessive pattern.
The recessive form of polycystic kidney, called ARPKD (autosomal recessive polycystic kidney disease) is less common than autosomal dominant polycystic kidney.
Mutations in the PKHD1 (chromosomal locus 6p12.2) cause ARPKD.[1][2]
It can present with Potter sequence.[3]
Contents
- 1 Clinical Features
- 2 Diagnosis
- 3 Treatment
- 4 References
- 5 External links
Clinical Features
The clinical presentation of ARPKD is highly variable. Up to 50% of affected neonates die of pulmonary hypoplasia, the result of oligohydramnios from severe intrauterine kidney disease. About 80% of those who survive the neonatal period are still alive after 10 years; however, one-third of them will have developed ESRD. Enlarged kidneys may be detected soon after birth as bilateral abdominal masses. Impaired urinary concentrating ability and metabolic acidosis ensue as tubular function deteriorates. Hypertension often occurs in the first few years of life. Kidney function deteriorates progressively from childhood into early adult life. Longer-term survivors frequently develop portal hypertension, esophageal varices, and hypersplenism from periportal fibrosis.
Micrograph of a von Meyenburg complex, a common finding in the liver in individuals with
polycystic kidney disease. Liver biopsy. Trichrome stain.
General presenting symptoms and signs include abdominal discomfort, hematuria, urinary tract infection, incidental discovery of hypertension, abdominal mass, elevated serum creatinine, or cystic kidneys on imaging studies, patients usually have renal pain, and develop renal insufficiency.
ARPKD-Specific: The classic presentation for ARPKD is systemic hypertension with progression to end-stage renal disease (ESRD) by the age of 15. In atypical presentation, a small number of ARPKD sufferers live to adulthood with some kidney function; but with significant deterioration in liver function.[4] This outcome is postulated to result from expression of the polycystic kidney and hepatic disease gene PKHD1, which is located on chromosome 6p.[5]
Diagnosis
Ultrasonography reveals large, echogenic kidneys. The diagnosis can be made in utero after 24 weeks of gestation in severe cases, but cysts generally become visible only after birth. The absence of renal cysts in either parent on ultrasonography helps to distinguish ARPKD from ADPKD in older patients. The wide range of different mutations and the large size of the gene complicate molecular diagnosis, although prenatal diagnosis is possible by gene linkage to the PKHD1 locus in families with a previous confirmed ARPKD birth.
The sensitivity of renal ultrasonography for the detection of ADPKD is 100% for subjects 30 years or older with a positive family history. Diagnostic criteria require two or more cysts in one kidney and at least one cyst in the contralateral kidney in young subjects, but four or more in subjects older than 60 years, because of the increased frequency of benign simple cysts. Most often, the diagnosis is made from a positive family history and imaging studies showing large kidneys with multiple bilateral cysts and possibly liver cysts. Before the age of 30 years, CT scan or T2-weighted MRI is more sensitive for detecting presymptomatic disease because the sensitivity of ultrasound falls to 95% for ADPKD type 1 and <70% for ADPKD type 2. Genetic counseling is essential for those being screened. It is recommended that screening for asymptomatic intracranial aneurysms should be restricted to patients with a personal or family history of intracranial hemorrhage. Intervention should be limited to aneurysms larger than 10 mm. Someone with this disease has a 5% chance of getting brain aneurysms.
Treatment
No specific therapy exists for ARPKD. Improvements in mechanical ventilation, neonatal support, blood pressure management, dialysis, and kidney transplantation have led to survival well into adulthood. Complications of hepatic fibrosis may necessitate liver transplantation. Future therapies may target aberrant cell signaling mechanisms, as in ADPKD.
At present, treatment is largely supportive, as there is no single therapy that has been shown to prevent the decline in kidney function. Hypertension control with a target blood pressure of 130/85 or less is recommended. Lower levels have been reported to slow the rate of loss of kidney function. A multidrug approach that includes agents to inhibit the renin-angiotensin system is frequently required. There is no compelling evidence to recommend a low-protein diet, especially in patients with advanced kidney dysfunction where optimizing nutritional status is important. Lipid-soluble antimicrobials, such as trimethoprim-sulfamethoxazole and quinolone antibiotics that have good tissue permeation, are the preferred therapy for infected kidney cysts. Pain-management occasionally requires cyst drainage by percutaneous aspiration, sclerotherapy with alcohol or, rarely, surgical drainage. Patients with ADPKD appear to have a survival advantage on either peritoneal or hemodialysis compared to patients with other causes of ESRD. Those undergoing kidney transplantation may require bilateral nephrectomy if the kidneys are massively enlarged or have been the site of infected cysts. Post-transplantation survival rates are similar to those of patients with other causes of kidney failure, but patients remain at risk for the extrarenal complications of ADPKD.
Studies in animal models of inherited cystic disease have identified promising therapeutic strategies, which are undergoing clinical research, including vasopressin V2 receptor antagonists (such as Tolvaptan), and mTOR inhibitors (such as Sirolimus or Everolimus).
References
- ^ Bergmann C, Küpper F, Dornia C, Schneider F, Senderek J, Zerres K (March 2005). "Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD)". Hum. Mutat. 25 (3): 225–31. doi:10.1002/humu.20145. PMID 15706593.
- ^ Zhang MZ, Mai W, Li C et al. (February 2004). "PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells". Proc. Natl. Acad. Sci. U.S.A. 101 (8): 2311–6. doi:10.1073/pnas.0400073101. PMC 356947. PMID 14983006.
- ^ Gillessen-Kaesbach G, Meinecke P, Garrett C, Padberg BC, Rehder H, Passarge E (February 1993). "New autosomal recessive lethal disorder with polycystic kidneys type Potter I, characteristic face, microcephaly, brachymelia, and congenital heart defects". Am. J. Med. Genet. 45 (4): 511–8. doi:10.1002/ajmg.1320450422. PMID 8465860.
- ^ Bisceglia, M et al. (2006). "Renal cystic diseases: a review". Advanced Anatomic Pathology (13): 26–56.
- ^ Sweeney, WE; Avner ED (2006). "Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPDK)". Cell Tissue Research (326): 671–685.
External links
- GeneReviews/NIH/NCBI/UW entry on Polycystic Kidney Disease, Autosomal Recessive
- ARPKD/CHF Alliance at http://www.arpkdchf.org, for information on ARPKD and Congenital Hepatic Fibrosis (CHF).
- Global Rare Diseases Patient Registry and Data Repository (GRDR) for clinical research: http://arpkd-chf.grdr.info/index.php
- The Polycystic Kidney Disease Foundation website - more details on trials, treatments, nutrition, and support.
|
Congenital malformations and deformations of urinary system (Q60–Q64, 753)
|
|
| Abdominal |
| Kidney |
- Renal agenesis/Potter sequence, Papillorenal syndrome
- cystic
- Polycystic kidney disease
- Meckel syndrome
- Multicystic dysplastic kidney
- Medullary sponge kidney
- Horseshoe kidney
- Renal ectopia
- Nephronophthisis
- Dent's disease
- Alport syndrome
|
|
| Ureter |
- Ectopic ureter
- Megaureter
- Duplicated ureter
|
|
|
| Pelvic |
| Bladder |
|
|
| Urethra |
- Epispadias
- Hypospadias
- Posterior urethral valves
|
|
|
| Vestigial |
|
|
|
Index of the urinary system
|
|
| Description |
- Anatomy
- Physiology
- Development
- Cells
|
|
| Disease |
- Electrolyte and acid-base
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
- Urine tests
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- Intravenous fluids
|
|
|
|
Cystic diseases
|
|
| Respiratory system |
- Langerhans cell histiocytosis
- Lymphangioleiomyomatosis
- Cystic bronchiectasis
|
|
| Skin |
- stratified squamous: follicular infundibulum
- Epidermoid cyst and Proliferating epidermoid cyst
- Milia
- Eruptive vellus hair cyst
- outer root sheath
- Trichilemmal cyst and Pilar cyst and Proliferating trichilemmal cyst and Malignant trichilemmal cyst
- sebaceous duct
- Steatocystoma multiplex and Steatocystoma simplex
- Keratocyst
- nonstratified squamous: Cutaneous ciliated cyst
- Hidrocystoma
- no epithelium: Pseudocyst of the auricle
- Mucocele
- other and ungrouped: Cutaneous columnar cyst
- Keratin implantation cyst
- Verrucous cyst
- Adenoid cystic carcinoma
- Breast cyst
|
|
| Human musculoskeletal system |
|
|
| Human digestive system |
- oral cavity: Cysts of the jaws
- Odontogenic cyst
- Periapical cyst
- Dentigerous cyst
- Odontogenic keratocyst
- Nasopalatine duct cyst
- liver: Polycystic liver disease
- Congenital hepatic fibrosis
- Peliosis hepatis
- bile duct: Biliary hamartomas
- Caroli disease
- Choledochal cysts
- Bile duct hamartoma
|
|
| Nervous system |
- Cystic leukoencephalopathy
|
|
| Genitourinary system |
- Polycystic kidney disease
- Autosomal dominant polycystic kidney
- Autosomal recessive polycystic kidney
- Medullary cystic kidney disease
- Congenital cystic dysplasia
|
|
| Other conditions |
- Hydatid cyst
- Von Hippel–Lindau disease
- Tuberous sclerosis
|
|
|
Diseases of cilia
|
|
| Structural |
- receptor: Polycystic kidney disease
- cargo: Asphyxiating thoracic dysplasia
- basal body: Bardet–Biedl syndrome
- mitotic spindle: Meckel syndrome
- centrosome: Joubert syndrome
|
|
| Signaling |
|
|
| Other/ungrouped |
- Alström syndrome
- Primary ciliary dyskinesia
- Senior–Løken syndrome
- Orofaciodigital syndrome 1
- McKusick–Kaufman syndrome
- Autosomal recessive polycystic kidney
|
|
|
See also: ciliary proteins
|
Index of cells
|
|
| Description |
- Structure
- Organelles
- peroxisome
- cytoskeleton
- centrosome
- epithelia
- cilia
- mitochondria
- Membranes
- Membrane transport
- ion channels
- vesicular transport
- solute carrier
- ABC transporters
- ATPase
- oxidoreduction-driven
|
|
| Disease |
- Structural
- peroxisome
- cytoskeleton
- cilia
- mitochondria
- nucleus
- scleroprotein
- Membrane
- channelopathy
- solute carrier
- ATPase
- ABC transporters
- other
- extracellular ligands
- cell surface receptors
- intracellular signalling
- Vesicular transport
- Pore-forming toxins
|
|
|
